Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present International Stem Cell Corp. (OTC: ISCO).

Full DD Report for ISCO

You must become a subscriber to view this report.


Recent News from (OTC: ISCO)

International Stem Cell Corporation Granted Key US Patent Protecting Lead Therapeutic Program
CARLSBAD, Calif., Aug. 21, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announ...
Source: GlobeNewswire
Date: August, 21 2018 07:00
International Stem Cell Corporation Announces Record Sales and Operating Results for the Three and Six-Months ended June 30, 2018
CARLSBAD, Calif., Aug. 15, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ( www.internationalstemcell.com ) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today...
Source: GlobeNewswire
Date: August, 15 2018 07:00
International Stem Cell Corporation Developed 3D Liver Structures
CARLSBAD, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announc...
Source: GlobeNewswire
Date: August, 06 2018 07:00
International Stem Cell Corporation Expands Manufacturing Capabilities for Biomedical Products
CARLSBAD, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that its wholly owned s...
Source: GlobeNewswire
Date: July, 10 2018 07:00
International Stem Cell Corporation Publishes Advanced Stem Cell Therapy Methodology in Stem Cells and Development Journal
CARLSBAD, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announc...
Source: GlobeNewswire
Date: June, 25 2018 07:00
International Stem Cell Corporation Doses First Patient of the Third Cohort in Parkinson's Disease Clinical Trial
CARLSBAD, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced tod...
Source: GlobeNewswire
Date: June, 11 2018 07:00
International Stem Cell Corporation to Launch Advanced Joint Supplement
CARLSBAD, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announc...
Source: GlobeNewswire
Date: June, 05 2018 07:00
International Stem Cell Corporation Published Technology for Cartilage Generation in Journal of Tissue Engineering and Regenerative Medicine Technology
CARLSBAD, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announce...
Source: GlobeNewswire
Date: May, 30 2018 07:00
International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 2018
CARLSBAD, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ( www.internationalstemcell.com ) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today ...
Source: GlobeNewswire
Date: May, 22 2018 07:00
Edison Issues Outlook on International Stem Cell (ISCO)
LONDON, UK / ACCESSWIRE / May 14, 2018 / International Stem Cell (OTCQB: ISCO) is an early-stage cell therapy company currently in clinical trials to treat Parkinson's disease (PD). In November, the company presented interim six-month results from the first cohort of four patients in its Pha...
Source: ACCESSWIRE IA
Date: May, 14 2018 11:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-141.551.551.551.551,269
2018-12-131.571.5521.581.5523,593
2018-12-121.57851.581.581.57851,615
2018-12-111.531.551.551.53751
2018-12-101.501.551.5591.501,035

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1421,2690.1576Cover
2018-12-136323,59317.5898Cover
2018-12-065812,49123.3240Cover
2018-12-0458515,1383.8644Cover
2018-12-039,45536,73425.7391Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ISCO.


About International Stem Cell Corp. (OTC: ISCO)

Logo for International Stem Cell Corp. (OTC: ISCO)

lt p gt International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells hpSCs and the development and commercialization of cell based research and cosmetic products. ISCO s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes eggs . hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial backgrounds, with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell . ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology www.lifelinecelltech.com , and stem cell based skin care products through its subsidiary Lifeline Skin Care www.lifelineskincare.com . lt /p gt

 

 

 

Current Management

  • Andrey Semechkin / CEO
    • Dr. Semechkin is a specialist in system analysis, strategic planning and corporate management. He is a member of the Russian Academy of Sciences and has been Deputy Director of Institute of System Analysis since . Professor Semechkin was awarded the Russian Government Award in Science and Technology in and has written several scientific books. He has over years experience creating and managing businesses across different industries and scientific sectors.
  • Sophia Garnette / VP, Legal, VP, Ops.
    • Ms. Garnette received her J.D. from the University of Miami School of Law and has experience in various aspects of corporate and biotechnology law, regulatory affairs, project management, and business operations. After joining the Company in March , she has held a variety of business and legal roles, including inhouse counsel, advisor to the CEO, and Vice Chairman of the Board of Directors for Lifeline Skin Care. Ms. Garnette holds a Bachelor s degree in Economics from San Francisco State University and has worked in the finance industries prior to beginning her legal career.
  • Russell Kern / CSO, EVP
    • Dr. Kern was trained in medical genetics, embryology and stem cell biology. He holds a Ph.D. degree in Human Physiology from the Russian Academy of Medical Sciences and has broad expertise in neuroscience, and was part of the team, along with scientists from the NYU Medical School that elucidated the physiological changes that occur in the brains of Parkinson s disease patients. Dr. Kern directs ISCO s R amp D programs including stem cell derivation, differentiation and the preclinical and clinical evaluation of stem cell derived cells and tissue. He has developed a general method of deriving highly pure populations of neural stem cells and dopaminergic neurons from pluripotent stems cells that is novel, practical and suitable for use in a clinical setting. Dr. Kern is a wellknown speaker on stem cell biology, including the use of stem cells for neurology and skin regeneration. He has more than publications in the field of Parkinson s disease and stem cell biology and he is an active member of the American Academy of Neurology, the Society for Neuroscience and the International Society for Stem Cell Research.
  • Investor Relations / IR
  • Donald Wright / CoChairman, Independent Director, Audit Committee Member, Compensation Committee Member
    • Mr. Wright brings to International Stem Cell Corporation over years of experience in starting and nurturing emerging growth companies, both public and private. He is President and Founder of Everett, Washingtonbased Confluence Capital Group Inc., www.confluencecap.com , which provides consulting services to institutional investors, debt holders and public and private companies. Prior to Confluence Capital, Mr. Wright was President and CEO of Pacific Aerospace amp Electronics, Inc., a company he founded in , took public and ran until . Under his leadership, Pacific Aerospace grew from annual sales of approximately million in to over million in . Earlier, Mr. Wright was President and CEO of Washingtonbased Component Concepts, Inc., a company he founded in . He is the recipient of numerous business and community awards, and was named one of the fastest growing companies in Washington State for , and by Deloitte amp Touche. Additionally he was recognized by Deloitte amp Touche as one of the fastest growing companies in the United States for , and . Mr. Wright served as an advisory board member for Central Washington University s School of Business for six years and completed the UCLA Director Training and Certification Program.
  • Andrey Semechkin / CoChairman
    • Dr. Semechkin is a specialist in system analysis, strategic planning and corporate management. He is a member of the Russian Academy of Sciences and has been Deputy Director of Institute of System Analysis since . Professor Semechkin was awarded the Russian Government Award in Science and Technology in and has written several scientific books. He has over years experience creating and managing businesses across different industries and scientific sectors.
  • Charles Casamento / Independent Director, Audit Committee Member, Compensation Committee Member
    • Mr. Casamento is currently Executive Director and Principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies. He was the president and CEO of Osteologix, Inc., a public biopharmaceutical company developing products for treating osteoporosis, from through . From through , he served as chairman of the board, president and CEO and was founder of Questcor Pharmaceuticals, Inc. Mr. Casamento formerly served as RiboGene, Inc. s president, CEO and chairman of the board from through until it merged with Cypros to form Questcor. He was cofounder, president and CEO of Interneuron Pharmaceuticals, Inc. Indevus , a biopharmaceutical company, from until . Mr. Casamento has also held senior management positions at Genzyme Corporation, American Hospital Supply, Johnson amp Johnson, HoffmannLaRoche, Inc. and Sandoz Inc. now Novartis . Mr. Casamento also serves on the Board of Directors of KineMed, Inc. and is a member of the Fordham University Science Council. He was formerly Vice Chairman of The Catholic medical Mission Board, a large international not for profit organization providing health care services to third world countries. He holds a bachelor s degree in Pharmacy from Fordham University and an M.B.A. from Iona College and was originally licensed to practice pharmacy in the states of New York and New Jersey.
  • Paul V. Maier / Independent Director, Audit Committee Member, Compensation Committee Member
    • Mr. Maier serves as a member of the board of directors and has over years of experience as a senior executive in biotechnology and pharmaceutical companies. Mr. Maier is currently an independent financial consultant. Previously, Mr. Maier was Senior Vice President and Chief Financial officer of Ligand Pharmaceuticals, Inc. NASDAQ: LGND a commercial stage biopharmaceutical company, a position he held from to . From to , Mr. Maier served as Vice President, Finance of DFS West, a division of DFS Group, LP a private multinational retailer. From to , Mr. Maier was employed by ICN Pharmaceuticals, a pharmaceutical and biotechnology research products company, where he held various executive positions in finance and general management in ICN as well as SPI Pharmaceuticals, a publicly held subsidiary. Mr. Maier has served on the boards of public and private companies. Mr. Maier received an MBA from Harvard Business School and a BS from Pennsylvania State University.

Current Share Structure

  • Market Cap: $6,226,721 - 03/15/2018
  • Authorized: 120,000,000 - 03/31/2017
  • Issue and Outstanding: 4,151,147 - 11/13/2017

 


Recent Filings from (OTC: ISCO)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 15 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 09 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 02 2018
Withdrawal of registration statement filed under the Securities Act
Filing Type: RWFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 21 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: January, 31 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 13 2017

 

 


Daily Technical Chart for (OTC: ISCO)

Daily Technical Chart for (OTC: ISCO)


Stay tuned for daily updates and more on (OTC: ISCO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ISCO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ISCO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ISCO and does not buy, sell, or trade any shares of ISCO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/